Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Clinical trial NCT05392751 · TERMINATED
Trial details
- NCT number
- NCT05392751
- Sponsor
- Endogena Therapeutics, Inc
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-02
- Primary completion
- 2024-04-24
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.